CARDINAL HEALTH INC News
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
see moreCARDINAL HEALTH INC Market News
5d
Cardinal Health Q3 Beat, Guidance Lift, Selloff
- Cardinal Health reported April 30 Q3 results with a non‑GAAP EPS beat and raised FY26 guidance, but a revenue miss, a $184M impairment and margin pressure sent CAH shares lower. Specialty strength (oncology, specialty pharma) contrasts with GLP‑1 and IRA headwinds; investors should track revenue mix, free cash flow and execution against guidance.
19d
Cardinal Health Compliance Risk Fuel Stock Rebound
Cardinal Health (CAH) is showing stock recovery despite lingering regulatory and legacy liabilities. Recent updates highlight ongoing compliance scrutiny tied to past misconduct, while CAH’s share price has rebounded from last year’s lows and sits below its 52-week high. Concurrent healthcare IT deals underscore shifting competitive dynamics that may affect Cardinal’s services and margins. This article summarizes material events and their near-term implications for investors.
30 Mar at 04:15
Cardinal Health CAH Remains Steady in S&P 500 Pulse
Cardinal Health (CAH) showed steady trading late in March as healthcare names drew defensive flows. With the Health Care Select Sector (XLV) outperforming, CAH’s scale and distribution strengths helped it weather margin pressure from generic pricing and legacy litigation. Investors should monitor upcoming quarterly results and Medical segment trends as potential catalysts.
23 Mar at 04:15
Cardinal Health: Specialty, ContinuCare Drive CAH.
Cardinal Health (CAH) has reported recent, concrete momentum: raised FY2026 EPS guidance to at least $10, specialty pharma revenue targets above $50B, successful ADSG integration, and the rollout of the ContinuCare™ Pathway. These developments—highlighted at the Leerink conference and in investor presentations—strengthen CAH’s earnings profile, bolster analyst confidence, and support S&P 500 investor interest.
16 Mar at 04:12
Cardinal Health Soars: Q2 Beat Fuels Buybacks Now!
Cardinal Health (CAH) surged after a strong Q2 FY2026 report that lifted guidance and continued aggressive share repurchases. Investor optimism—highlighted by a Weiss Ratings uptick—remains the short-term catalyst, while execution in specialty services and reimbursement uncertainty are primary risks. No new, material developments emerged in the most recent week.
02 Mar at 04:12
Cardinal Health Order Express Fuels Specialty Push
Cardinal Health (CAH) bolstered its specialty and logistics positioning this week with the rollout of the Order Express high-speed logistics platform and the finalized acquisition of Specialty Networks. These concrete moves — plus renewed competitive dynamics after OptumRx contract shifts — point to revenue diversification, margin pressure alleviation, and measurable operational improvements investors should track.
23 Feb at 04:12
Cardinal Health Climbs Near 52-Week High CAH Rally
Cardinal Health (CAH) gained 2.17% on Feb 17, 2026, closing at $225.58 and trading just below its 52-week high of $230.81. The move outpaced healthcare peers amid a modest S&P 500 uptick; trading volume was slightly below the 50-day average. No other major sector-specific headlines emerged in the past week, leaving technical momentum and upcoming catalysts as primary drivers for investors.